---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-038997"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:41:51.847089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics Q1 net loss widens to $14.3M; de-prioritizes AML/MDS Phase 3

## Summary
- Net loss of $14.3M in Q1 2023 vs $2.2M in Q1 2022, driven by increased R&D and warrant liability changes.
- Cash and cash equivalents of $129.4M as of March 31, 2023, boosted by $101.4M net proceeds from January public offering.
- De-prioritized Phase 3 development of briquilimab as conditioning for AML/high-risk MDS; now focusing on chronic spontaneous urticaria and low-intermediate risk MDS.
- Announced positive clinical data from Phase I/II of briquilimab in sickle cell disease: all three patients engrafted, 100% donor myeloid chimerism at 60 days.
- Strengthened board with Vishal Kapoor; appointed Daniel Adelman as Acting CMO.

## SEC filing metadata
- accession: 0001213900-23-038997
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/0001213900-23-038997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/ea178442-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-038997
- JSON: https://secwatch.observer/filing/0001213900-23-038997.json
- Plain text: https://secwatch.observer/filing/0001213900-23-038997.txt

## Key facts
- Earnings Releases
  Jasper Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $14.3 million.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss was $14.3 million
  - Result: reported results
  source text: On May 12, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2023 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/0001213900-23-038997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.